On June 14, 2018 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it has initiated dosing in its phase 1 clinical trial of TTI-622 (SIRPaFc-IgG4), a checkpoint inhibitor of the innate immune system, in relapsed or refractory lymphoma or myeloma (Press release, Trillium Therapeutics, JUN 14, 2018, View Source [SID1234527309]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TTI-622 is a fusion protein that blocks the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors. CD47 binds to SIRPa on macrophages and delivers a "do not eat" signal that inhibits the ability of macrophages to engulf and destroy cancer cells. Preclinical studies have shown that TTI-622 has anti-tumor activity across a range of hematologic tumors.

TTI-622 is the second SIRPaFc decoy receptor that Trillium has advanced into the clinic. TTI-621 (SIRPaFc-IgG1), which consists of the same CD47-binding domain of human SIRPa as TTI-622 but linked to an IgG1 Fc region, is currently in two multicenter trials and has produced positive signals of activity in mycosis fungoides, Sézary syndrome and diffuse large B-cell lymphoma patients. The different pharmacologic properties of TTI-621 and TTI-622 will allow Trillium to explore the relationships between the level of CD47 blockade, Fc isotype, tolerability and anti-tumor activity in patients.

"This is an exciting time for Trillium as we initiate clinical development with our second CD47 blocking agent," commented Dr. Yaping Shou, Trillium’s Chief Medical Officer. "TTI-622 deepens our presence in the CD47 space, and its minimal binding to human erythrocytes could confer best-in-class status among IgG4-based blocking agents currently in development."

A two-part, multicenter, open-label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma or multiple myeloma has been initiated. In the phase 1a dose-escalation part, patients will be enrolled in sequential dose cohorts to receive TTI-622 once weekly to characterize safety, tolerability, pharmacokinetics, and to determine the maximum tolerated dose. In the phase 1b part, patients will be treated with TTI-622 in combination with rituximab, a proteasome inhibitor-containing regimen, or a PD-1 inhibitor. Rituximab and proteasome inhibitors may provide additional "eat" signals that could enhance the efficacy of TTI-622. A PD-1 inhibitor may help amplify any anti-tumor T cell response generated by TTI-622.

On June 14, 2018 Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that Troy Wilson, Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference in New York on Thursday, June 21, 2018 at 11:00 a.m. ET / 8:00 a.m. PT (Press release, Kura Oncology, JUN 14, 2018, View Source [SID1234527310]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

On June 13, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the 2018 JMP Securities Life Sciences Conference, being held in New York City on June 20-21, 2018 (Press release, Leap Therapeutics, JUN 13, 2018, View Source;p=RssLanding&cat=news&id=2354356 [SID1234527292]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JMP Securities Life Sciences Conference – Leap Presentation Details:
Date: Wednesday, June 20, 2018
Time: 11:30 A.M.

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at www.investors.leaptx.com, where a replay of the event will also be available for a limited time.

On June 13, 2018 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), reported that the Medical College of Wisconsin has treated its first patient in a Phase 1 trial studying Actinium’s Actimab-A in combination with CLAG-M for patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) (Press release, Actinium Pharmaceuticals, JUN 13, 2018, View Source [SID1234527311]). This Phase 1 dose-escalation trial will study a single administration of Actimab-A following treatment of CLAG-M and will evaluate safety and tolerability, response rates, rates of bone marrow transplant (BMT), progression-free survival (PFS), and overall survival (OS).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Mark Berger, Actinium’s Chief Medical Officer said, "We are grateful for all of the hard work that the team at MCW has put in to get to this important milestone. Actimab-A has demonstrated promising activity as a single agent in difficult to treat patient populations that we attribute to its targeting ability, potency and tolerability. We are excited to be leveraging these strengths of Actimab in a combination regimen to bring this potentially important therapy to a greater number of patients in indications that need improved outcomes. We are confident that the addition of Actimab to a salvage chemotherapy regimen has the potential to improve outcomes through improved response rates and by increasing the number of patients that can receive a bone marrow transplant."

Actimab-A is an ARC or Antibody Radio-Conjugate comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the radioisotope actinium-225. CD33 is a marker expressed on AML cells of virtually all AML patients. Actinium’s CD33 ARC has been studied in over 100 patients to date and is the only CD33 targeting agent being studied in a broad range of diseases in which the CD33 antigen is expressed including AML, myelodysplastic syndrome (MDS) and multiple myeloma. CLAG-M is a salvage chemotherapy regimen commonly used to treat patients with AML that consists of cladribine, cytarabine, filgrastim, and mitoxantrone.

Sandesh Seth, Actinium’s Chairman and CEO said, "Through the utilization of targeted radioisotopes we are able to add a new modality of treatment to a salvage cytotoxic chemotherapy regimen with the aim of improving efficacy. Further, we can apply our ARC technology to targeted conditioning to enable a bone marrow transplant that we will explore in this trial as well as our anticipated Actimab-MDS trial. In short time, our team has leveraged our capabilities to create the broadest CD33 program in terms of indications and addressable patient population. We believe our approach for this program which is supported by the strong hypothesis that combinations of targeted internalized radiation using ARC’s with chemotherapeutics is underpinned by a strong biologic rationale that can yield the best in class CD33 program".

About Our CD33 Program

We are developing a potentially best in class CD33 program using our ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter Actinium-225 (Ac225-lintuzumab). Our CD33 program was originally developed in conjunction with Memorial Sloan Kettering Cancer Center and has been studied in over 100 patients to date. CD33 is a marker shown to be expressed on cancerous blast cells of virtually all patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and approximately 25%- 35% of patients with multiple myeloma. Actinium-225 is highly differentiated radioisotope that emits high amounts of energy through the release of four alpha-particles that can cause double-stranded breaks in DNA with known resistance mechanisms to Actinium-225. Given the limited distance of its energy in the body, it is potentially sparing of non-targeted cells leading to better tolerability and less toxicities.

Our CD33 program includes a Phase 2 clinical trial of for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy an indication we have been granted Orphan Drug designation for in the US and EU. We are conducting a Phase 1 trial for patients with refractory multiple myeloma and planning to start a clinical trial for targeted conditioning prior to a bone marrow transplant for patients with high-risk MDS. We are studying Ac225-lintuzumab in combination with the chemotherapy regimen CLAG-M. We intend to continue to develop our CD33 program as a targeted therapy and for targeted conditioning of the bone marrow with Ac225-lintuzumab as a single agent and with novel combinations.

On June 13, 2018 Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, reported that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20, 2018 (Press release, Editas Medicine, JUN 13, 2018, View Source;p=RssLanding&cat=news&id=2354406 [SID1234527295]). Details of the panel are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel: Gene Editing – From Science to Reality
Date: Wednesday, June 20, 2018
Time: 8:00 a.m.
Location: St. Regis Hotel, New York